Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $3 to $3.1.
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $3 to $3.1.